Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies

A hallmark of patients with autoimmune polyendocrine syndrome type 1 (APS-1) is serological neutralizing autoantibodies against type 1 interferons (IFN-I). The presence of these antibodies has been associated with severe course of COVID-19. The aims of this study were to investigate SARS-CoV-2 vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolff, Anette S.B., Hansen, Lena, Grytaas, Marianne Aa., Oftedal, Bergithe E., Breivik, Lars, Zhou, Fan, Hufthammer, Karl Ove, Sjøgren, Thea, Olofsson, Jan Stefan, Trieu, Mai Chi, Meager, Anthony, Jørgensen, Anders P., Lima, Kari, Greve-Isdahl Mohn, Kristin, Langeland, Nina, Cox, Rebecca Jane, Husebye, Eystein S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251722/
https://www.ncbi.nlm.nih.gov/pubmed/37346050
http://dx.doi.org/10.1016/j.isci.2023.107084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251722/
https://www.ncbi.nlm.nih.gov/pubmed/37346050
http://dx.doi.org/10.1016/j.isci.2023.107084

Ejemplares similares